What is Wedbush’s Forecast for NovoCure FY2026 Earnings?

NovoCure Limited (NASDAQ:NVCR) – Wedbush raised their FY2026 earnings per share estimates for NovoCure in a report released on Monday, December 2nd. Wedbush analyst D. Nierengarten now expects that the medical equipment provider will post earnings of ($1.14) per share for the year, up from their prior estimate of ($1.29). Wedbush has a “Neutral” rating and a $29.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share. Wedbush also issued estimates for NovoCure’s FY2027 earnings at ($0.88) EPS.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. The business had revenue of $155.10 million during the quarter, compared to analysts’ expectations of $143.95 million. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm’s quarterly revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.46) earnings per share.

A number of other research firms have also commented on NVCR. HC Wainwright reissued a “buy” rating and issued a $38.00 target price (up previously from $30.00) on shares of NovoCure in a report on Monday. Evercore ISI raised NovoCure from an “in-line” rating to an “outperform” rating and lifted their target price for the stock from $18.00 to $30.00 in a report on Monday. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, NovoCure currently has an average rating of “Moderate Buy” and an average price target of $30.33.

NovoCure Stock Down 4.2 %

Shares of NASDAQ:NVCR opened at $29.23 on Thursday. The stock has a fifty day simple moving average of $17.46 and a two-hundred day simple moving average of $18.58. The stock has a market capitalization of $3.16 billion, a price-to-earnings ratio of -20.88 and a beta of 0.75. NovoCure has a 12-month low of $11.66 and a 12-month high of $32.60. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27.

Institutional Trading of NovoCure

Large investors have recently modified their holdings of the company. Nordwand Advisors LLC lifted its position in NovoCure by 100.0% during the third quarter. Nordwand Advisors LLC now owns 3,029,824 shares of the medical equipment provider’s stock valued at $47,356,000 after purchasing an additional 1,514,824 shares in the last quarter. Renaissance Technologies LLC lifted its position in NovoCure by 171.9% during the second quarter. Renaissance Technologies LLC now owns 760,175 shares of the medical equipment provider’s stock valued at $13,022,000 after purchasing an additional 480,600 shares in the last quarter. Panagora Asset Management Inc. lifted its position in NovoCure by 309.8% during the second quarter. Panagora Asset Management Inc. now owns 409,794 shares of the medical equipment provider’s stock valued at $7,020,000 after purchasing an additional 309,805 shares in the last quarter. AQR Capital Management LLC lifted its position in NovoCure by 234.2% during the second quarter. AQR Capital Management LLC now owns 431,445 shares of the medical equipment provider’s stock valued at $7,391,000 after purchasing an additional 302,351 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in NovoCure by 56.8% during the second quarter. Bank of New York Mellon Corp now owns 419,960 shares of the medical equipment provider’s stock valued at $7,194,000 after purchasing an additional 152,185 shares in the last quarter. Institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.